CD274 and small cell lung carcinoma: Representative first‐line treatment for patients with ES‐SCLC consists of platinum and etoposide or irinotecan therapy;5, 6 however, two recent clinical trials have revealed that the addition of anti‐programmed death‐ligand 1 antibody (anti‐PD‐L1) to platinum‐etoposide therapy statistically prolonged progression‐free survival (PFS) compared to that with platinum‐etoposide therapy.